Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial

RCT (n=166) found that pemafibrate 0.2mg per day, and 0.4mg per day significantly reduced triglyceride levels vs placebo (-44.3%, -45.1% and -10.8% respectively, p<0.001). The incidence of adverse effects were similar across the pemafibrate and placebo groups